Tobacco control · 2014
Use of e-cigarettes by individuals with mental health conditions.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cummins Sharon E, Zhu Shu-Hong, Tedeschi Gary J, Gamst Anthony C, Myers Mark G
Аннотация
BACKGROUND: Individuals with mental health conditions (MHC) have disproportionately high tobacco-related morbidity and mortality due to high smoking prevalence rates. As high consumers of cigarettes, smokers with MHC may consider using e-cigarettes as an alternative form of nicotine delivery.
OBJECTIVE: Examination of the susceptibility to use e-cigarettes by individuals with MHC.
METHODS: A U.S. population survey with a national probability sample (n=10,041) was used to assess ever use and current use of regular cigarettes, e-cigarettes, and U.S. Food and Drug Administration-approved pharmacotherapy for smoking cessation. Survey respondents provided information about whether they had been diagnosed with an anxiety disorder, depression, or other MHC.
RESULTS: Individuals with MHC were more likely to have tried e-cigarettes (14.8%) and to be current users of e-cigarettes (3.1%) than those without MHC (6.6% and 1.1%, respectively; p<0.01). Ever smokers with MHC were also more likely to have tried approved pharmacotherapy (52.2% vs. 31.1%, p<0.01) and to be currently using these products (9.9% vs. 3.5%, p<0.01) than those without MHC. Additionally, current smokers with MHC were more susceptible to future use of e-cigarettes than smokers without MHC (60.5% vs. 45.3%, respectively, p<0.01).
CONCLUSIONS: Smokers with MHC are differentially affected by the rise in popularity of e-cigarettes. Clinical interventions and policies for tobacco control on e-cigarettes should take into account the possible outcomes and their implications for this priority population.
OBJECTIVE: Examination of the susceptibility to use e-cigarettes by individuals with MHC.
METHODS: A U.S. population survey with a national probability sample (n=10,041) was used to assess ever use and current use of regular cigarettes, e-cigarettes, and U.S. Food and Drug Administration-approved pharmacotherapy for smoking cessation. Survey respondents provided information about whether they had been diagnosed with an anxiety disorder, depression, or other MHC.
RESULTS: Individuals with MHC were more likely to have tried e-cigarettes (14.8%) and to be current users of e-cigarettes (3.1%) than those without MHC (6.6% and 1.1%, respectively; p<0.01). Ever smokers with MHC were also more likely to have tried approved pharmacotherapy (52.2% vs. 31.1%, p<0.01) and to be currently using these products (9.9% vs. 3.5%, p<0.01) than those without MHC. Additionally, current smokers with MHC were more susceptible to future use of e-cigarettes than smokers without MHC (60.5% vs. 45.3%, respectively, p<0.01).
CONCLUSIONS: Smokers with MHC are differentially affected by the rise in popularity of e-cigarettes. Clinical interventions and policies for tobacco control on e-cigarettes should take into account the possible outcomes and their implications for this priority population.